Emergent BioSolutions | 营业费用



金融业
股票价格
USD
资产
USD 1.82B
现金及等价物
USD 111.7M
销售成本
USD 381.2M
流动资产
USD 679.5M
流动负债
USD 651.3M
债务
USD 903.2M
股息收益率
0
EBIT
USD -148.1M
EBITDA
USD -113.5M
员工
1.6K
EPS每股收益
USD -0.77
股本和储备
USD 649.3M
销售毛利
USD 10M
债务利息支出
USD 17.9M
贷款资金
USD 446.5M
市值
USD 120.6M
净收入
USD -261.3M
营业费用
USD 555.9M
营业利润
USD -218M
普通股股本
USD 100K
PE价格收益
14.4
税前利润
USD -130.8M
销售收入
USD 276.6M
销售和管理费用
USD 182.8M
股票
USD 328.9M
贸易债权人
USD 112.2M
应收帐款人
USD 290.1M


营业费用 更改 日
Acadia Pharmaceuticals USD 242.88M 10.68M 2025-09
Akebia Therapeutics USD 43.82M 16.98M 2025-03
ALKERMES USD 1.73B 1.44B 2025-09
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amarin USD 51.37M 14.6M 2025-09
ANI Pharmaceuticals USD 505.82M 309.62M 2025-09
BioMarin Pharmaceutical USD 807.82M 259.3M 2025-09
Coherus Biosciences USD 53.03M 43.41M 2025-03
Emergent BioSolutions USD 555.9M 242.7M 2023-06
Exact Sciences USD 875.74M 62.51M 2025-09
Exelixis USD 362.75M 21.35M 2025-12
Glaxosmithkline GBP 7.77B 2.22B 2025-09
Heron Therapeutics USD 38.47M 4M 2024-09
Ionis Pharmaceuticals USD 316.9M 4.69M 2025-09
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Lexicon Pharmaceuticals USD 57M 10.54M 2024-06
Lonza CHF 3.09B 564M 2024-12
Merck USD 10.16B 558M 2025-12
Moderna USD 1.54B 259M 2025-12
Myriad Genetics USD 229M 3.4M 2025-09
Nektar Therapeutics USD 85.09M 109.3M 2025-09
Neurocrine Biosciences USD 577.6M 22M 2025-12
Pacira USD 166.36M 4.5M 2025-09
Pfizer USD 12.91B 79.89B 2025-12
PTC Therapeutics USD 207.52M 6.21M 2025-09
Sanofi EUR 10.51B 1.21B 2025-12
Sarepta Therapeutics USD 462.23M 33.28M 2025-09
United Therapeutics USD 6.59B 6.07B 2025-09
Vanda Pharmaceuticals USD 466M 20.33M 2025-09
Xoma USD 22.84M 1.67M 2024-09


Emergent BioSolutions 营业费用 - 当前值，历史数据，预测，统计，图表和经济日历 - Feb 2026.